Antywitaminy K i B9 w zastosowaniach medycznych

• Autorzy: Katarzyńska J.
• Języki publikacji: PL

Słowa kluczowe

PL

antywitaminy; antywitamina K; antywitamina B9

EN

antivitamin; antivitamin K; antivitamin B9; vitamin K antagonist; vitamin B9 antagonist

• Wydawca: Politechnika Łódzka, Wydział Chemiczny
• Czasopismo: Eliksir
• Rocznik: 2016
• Tom: nr 1
• Strony: 27--32
• Opis fizyczny: Bibliogr. 32 poz., rys. kolor.

Twórcy

autor

Katarzyńska J.

• Instytut Chemii Organicznej, Wydział Chemiczny, Politechnika Łódzka

Bibliografia

• [1] Zelder F., Sonnay M., Prieto L., 2015, Antivitamins for medicinal applications, ChemBioChem, 16, 1264-1278.
• [2] Dam H., 1935, The antihaemorrhagic vitamin of the chick.: occurrence and chemical nature, Nature, 135, 652-653.
• [3] Cranenburg E. C. M., Schurgers L. J., Vermeer C., 2007, Vitamin K: the coagulation vitamin that became omnipotent, Thromb. Haemostasis, 98, 120-125.
• [4] Hauschka P. V., Lian J. B.,. Gallop P. M., 1975, Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue, Proc. Natl. Acad. Sci. USA, 72, 3925-3929.
• [5] Schofield F. W., 1922, A brief account of a disease in cattle simulating hemorrhagic septicemia due to feeding sweet clover, Can. Vet. Record, 3, 74-78.
• [6] Link K. P., 1959, The discovery of dicumarol and its sequels, Circulation, 19, 97-107.
• [7] Griminger P., 1987, Vitamin K Antagonists: The First 50 Years, J. Nutr., 117, 1325-1329.
• [8] Tee Horst W. P., Felix E. L., 1943, 2,3-Dichloro-1,4-naphthoquinone, Ind. and Eng. Chem., 35, 1255-1259.
• [9] Matthews D. A., Alden R. A., Bolin J. T., Freer S. T., Hamlin R., Xuong N., Kraut J., Poe M., Williams M., Hoogsteen K., 1977, Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate, Science, 197, 452-455.
• [10] Hanley J. P., 2004, Warfarin reversal, J. Clin. Pathol., 57, 1132-1139.
• [11] Ikawa M., Stahmann M. A., Link K. P., 1944, Studies on 4-hydroxycoumarins. V. The condensation of α,β-unsaturated ketones with 4-hydroxycoumarin, J. Am. Chem. Soc., 66, 902-906.
• [12] Shapiro S., Ciferri F. E., 1957, Intramuscular administration of the anticoagulant warfarin (Coumadin) sodium, JAMA J. Am. Med. Assoc., 165, 1377-1380.
• [13] Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E., 2004, The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 204S-233S.
• [14] Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G., 2008, Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition), Chest, 133, 160S-198S.
• [15] Hankey G. J., Eikelboom J. W., 2011, Dabigatran etexilate: a new oral thrombin inhibitor, Circulation, 123, 1436-1450.
• [16] Perzborn E., Roehrig S., Straub A., Kubitza D., Misselwitz F., 2011, The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor, Nat. Rev. Drug Discovery, 10, 61-75.
• [17] Angier R. B., Boothe J. H., Hutchings B. L., Mowat J. H., Semb J., Stokstad E. L. R., Subbarow Y., Waller C. W., Cosulich D. B., Fahrenbach M. J, Hultquist M. E., Kuh E., Seeger N, D, R, Sickels J. P., Smith J. M. jr., 1946, The structure and synthesis of the liver L. casei , FactorScience, 103, 667-669.
• [18] Shive W., Ackermann W. W., Gordon M., Getzendaner M. E., Eakin R. E., 1947, 5(4)-Amino-4(5)-imidazolecarboxamide, a precursor of purines, J. Am. Chem. Soc., 69, 725-726.
• [19] Pereira M. P., Kelley S. O., 2011, Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells, J. Am. Chem. Soc., 133, 3260-3263.
• [20] G-Dayanandan N., Paulsen J. L., Viswanathan K., Keshipeddy S., Lombardo M. N., Zhou W., Lamb K. M., Sochia A. E., Alverson J. B., Priestley N. D., Wright D. L., Anderson A. C., 2014, Propargyl-linked antifolates are dual inhibitors of Candida albicans and Candida glabrata, J. Med. Chem., 57, 2643-2656.
• [21] Trefouel J., Trefouel J., Nitti F., Bovet D., 1935, Activite du p-aminophenylsulfamide sur les infections streptococciques experimentales de la souris et du lapin, CR Soc. Biol., 120, 756-758.
• [22] Stokstad E. L. R., Jukes T. H., 1987, Sulfonamides and folic acid antagonists: a historical review, J. Nutr., 117, 1335-1341.
• [23] Zejca A., Gorczyca M., Chemia leków, Wydawnictwo Lekarskie PZWL, wyd. II, Warszawa 2004.
• [24] Murray R. K., Granner D. K., Mayes P. A., Rodwell V. W., Biochemia Harpera, Wydawnictwo Lekarskie PZWL, Warszawa 2002.
• [25] Smith J. M., Cosulich D. B., Hultquist M. E., Seeger D. R., 1948, The chemistry of certain pteroylglutamic acid antagonists, Trans. N. Y.Acad. Sci., 10, 82-83.
• [26] Heidelberger C., Chaudhuri N. K., Danneberg P., Mooren D., Griesbach L., Duschinsky R., Schnitzer R. J., Pleven E., Scheiner J., 1957, Fluorinated pyrimidines, a new class of tumour-inhibitory compounds, Nature, 179, 663-666.
• [27] Farber S., Diamond L. K., Mercer R. D., Sylvester R. F., Wolff J. A., 1948, Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin), N. Engl. J. Med., 238, 787-793.
• [28] Rajagopalan P. T. R., Zhang Z. Q., McCourt L., Dwyer M, Benkovic S. J., Hammes G. G, 2002, Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics, Proc. Natl. Acad. Sci. USA, 99, 13481-13486.
• [29] Visentin M., Zhao R., Goldman I. D., 2012, Antifolates, Hematol. Oncol. Clin. North Am., 26, 629-648.
• [30] Golani L. K., George C., Zhao S., Raghavan S., Orr S., Wallace A., Wilson M. R., Hou Z., Matherly L. H., Gangjee A., 2014, Structure- activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter, J. Med. Chem., 57, 8152-8166.
• [31] Muller C., 2013, Folate-based radiotracers for PET imaging - update and perspectives, Molecules, 18, 5005-5031.
• [32] Pereira M. P., Kelley S. O., 2011, Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells, J. Am. Chem. Soc., 133, 3260-3263.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).